Technology ID
TAB-4330
Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use
E-Numbers
E-025-2006-0
Lead Inventor
O'Keefe, Barry (NCI)
Co-Inventors
McMahon, James (NCI)
Mori, Toshiyuki (NCI)
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Lead IC
NCI
ICs
NCI
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted)
Competitive Advantages:
- Highly Potent Broad-Spectrum Antiviral Lectin
- Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.
Commercial Applications:
- Microbicide that can prevent viral transmission
- Therapeutic against enveloped virus-mediated diseases
Licensing Contact: